These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 8891576

  • 1. Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists.
    Piercey MF, Hoffmann WE, Smith MW, Hyslop DK.
    Eur J Pharmacol; 1996 Sep 19; 312(1):35-44. PubMed ID: 8891576
    [Abstract] [Full Text] [Related]

  • 2. Excitation of type II anterior caudate neurons by stimulation of dopamine D3 receptors.
    Piercey MF, Hyslop DK, Hoffmann WE.
    Brain Res; 1997 Jul 11; 762(1-2):19-28. PubMed ID: 9262154
    [Abstract] [Full Text] [Related]

  • 3. Dopamine receptor agonist potencies for inhibition of cell firing correlate with dopamine D3 receptor binding affinities.
    Kreiss DS, Bergstrom DA, Gonzalez AM, Huang KX, Sibley DR, Walters JR.
    Eur J Pharmacol; 1995 Apr 24; 277(2-3):209-14. PubMed ID: 7493610
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. D1 dopamine receptor activity of anti-parkinsonian drugs.
    Fici GJ, Wu H, VonVoigtlander PF, Sethy VH.
    Life Sci; 1997 Apr 24; 60(18):1597-603. PubMed ID: 9126882
    [Abstract] [Full Text] [Related]

  • 7. The behavioural effects of pramipexole, a novel dopamine receptor agonist.
    Maj J, Rogóz Z, Skuza G, Kołodziejczyk K.
    Eur J Pharmacol; 1997 Apr 11; 324(1):31-7. PubMed ID: 9137910
    [Abstract] [Full Text] [Related]

  • 8. Antiparkinson concentrations of pramipexole and PHNO occupy dopamine D2(high) and D3(high) receptors.
    Seeman P, Ko F, Willeit M, McCormick P, Ginovart N.
    Synapse; 2005 Nov 11; 58(2):122-8. PubMed ID: 16088951
    [Abstract] [Full Text] [Related]

  • 9. Behavioral and neurochemical data suggest functional differences between dopamine D2 and D3 receptors.
    Svensson K, Carlsson A, Huff RM, Kling-Petersen T, Waters N.
    Eur J Pharmacol; 1994 Oct 03; 263(3):235-43. PubMed ID: 7843260
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pramipexole--a new dopamine agonist for the treatment of Parkinson's disease.
    Bennett JP, Piercey MF.
    J Neurol Sci; 1999 Feb 01; 163(1):25-31. PubMed ID: 10223406
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.
    Utsumi H, Okuma Y, Kano O, Suzuki Y, Iijima M, Tomimitsu H, Hashida H, Kubo S, Suzuki M, Nanri K, Matsumura M, Murakami H, Hattori N, Tokyo Parkinson's Disease Study Group.
    Intern Med; 2013 Feb 01; 52(3):325-32. PubMed ID: 23370739
    [Abstract] [Full Text] [Related]

  • 13. Differential induction of adenylyl cyclase supersensitivity by antiparkinson drugs acting as agonists at dopamine D1/D2/D3 receptors vs D2/D3 receptors only: parallel observations from co-transfected human and native cerebral receptors.
    Aloisi G, Silvano E, Rossi M, Millan MJ, Maggio R.
    Neuropharmacology; 2011 Feb 01; 60(2-3):439-45. PubMed ID: 21035472
    [Abstract] [Full Text] [Related]

  • 14. The discriminative stimulus effects of dopamine D2- and D3-preferring agonists in rats.
    Koffarnus MN, Greedy B, Husbands SM, Grundt P, Newman AH, Woods JH.
    Psychopharmacology (Berl); 2009 Apr 01; 203(2):317-27. PubMed ID: 18807248
    [Abstract] [Full Text] [Related]

  • 15. Pre-clinical studies of pramipexole: clinical relevance.
    Hubble JP.
    Eur J Neurol; 2000 May 01; 7 Suppl 1():15-20. PubMed ID: 11054154
    [Abstract] [Full Text] [Related]

  • 16. Effects of the D3 preferring dopamine agonist pramipexole on sleep and waking, locomotor activity and striatal dopamine release in rats.
    Lagos P, Scorza C, Monti JM, Jantos H, Reyes-Parada M, Silveira R, Ponzoni A.
    Eur Neuropsychopharmacol; 1998 May 01; 8(2):113-20. PubMed ID: 9619689
    [Abstract] [Full Text] [Related]

  • 17. Agonistic actions of pergolide on firing activity of dopamine neurons in substantia nigra compacta area.
    Zhang XX, Jin GZ, Wei YF.
    Zhongguo Yao Li Xue Bao; 1995 Sep 01; 16(5):423-7. PubMed ID: 8701759
    [Abstract] [Full Text] [Related]

  • 18. Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors.
    Perachon S, Schwartz JC, Sokoloff P.
    Eur J Pharmacol; 1999 Feb 05; 366(2-3):293-300. PubMed ID: 10082211
    [Abstract] [Full Text] [Related]

  • 19. The activity of pramipexole in the mouse forced swim test is mediated by D2 rather than D3 receptors.
    Siuciak JA, Fujiwara RA.
    Psychopharmacology (Berl); 2004 Sep 05; 175(2):163-9. PubMed ID: 14985923
    [Abstract] [Full Text] [Related]

  • 20. Treatment of Parkinson's disease should begin with a dopamine agonist.
    Montastruc JL, Rascol O, Senard JM.
    Mov Disord; 1999 Sep 05; 14(5):725-30. PubMed ID: 10495032
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.